Function and Evolutionary Origins of the RAG Endonuclease
RAG 核酸内切酶的功能和进化起源
基本信息
- 批准号:10231071
- 负责人:
- 金额:$ 52.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-11 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adaptive Immune SystemAddressAdherenceAntigen ReceptorsBindingBiochemicalBiochemistryBiologicalBiological AssayBiophysicsCatalytic DomainCellsChimeric ProteinsCleaved cellComplexCoupledCouplingCryoelectron MicroscopyCrystallizationDNADNA BindingDNA Binding DomainDNA RepairDNA Repair GeneDNA Transposable ElementsDangerousnessData SetDefectDevelopmentEnzymesEventEvolutionFailureFamilyGenetic RecombinationGenomeGenome StabilityGenomic InstabilityGenomicsGoalsHeartHematopoietic NeoplasmsHigh-Throughput Nucleotide SequencingHuman ChromosomesHuman GenomeImmune systemImmunityIn VitroJawLymphocyteMalignant NeoplasmsMammalian CellMapsMediatingMethodsModelingMolecular ConformationMusMutant Strains MicePeptide Signal SequencesProcessProtein BiochemistryProteinsReceptor GeneRegulationResolutionRoentgen RaysSourceStructureSynapsesSystemTransposaseV(D)J RecombinationVertebratesWorkX-Ray Crystallographyadaptive immunitybiophysical propertiesendonucleaseexperimental studyfascinatein vitro activityin vivoinsightlensleukemia/lymphomamalignant lymphocytemammalian genomemolecular modelingmutantnovelpreventrecombinasesingle moleculestemtooltumorigenesisunpublished works
项目摘要
!
SUMMARY
The RAG1/RAG2 recombinase, which initiates V(D)J recombination, is a defining feature of jawed
vertebrate adaptive immunity and is thought to have evolved from a transposable element. Key aspects of
RAG biochemistry and in vivo regulation are not understood, leaving large gaps in our understanding of the
mechanisms by which RAG contributes to genome instability and the development of cancer. The Transib
and ProtoRAG transposons, which encode RAG-like transposases, provide an entirely new "toolbox" with
which to fill these gaps. In unpublished work, we have: i) determined the structure of ProtoRAG-DNA
complexes by cryo-electron microscopy (EM); ii) obtained crystals of Transib transposase that diffract x-rays
to ~3Å resolution; iii) identified a key component of the mechanism that directs coordinated (coupled) DNA
cleavage by RAG; and iv) discovered two mechanisms that suppress RAG-mediated transposition in vivo.
We will use these novel tools and findings to accomplish our central objective: to determine the
biochemical, structural, and regulatory mechanisms that have evolved to orchestrate RAG function
and to ascertain the biological consequences of failures of these mechanisms. Our proposal is
organized around three core questions. First, what mechanisms explain coupled cleavage by RAG and why
do those mechanisms break down? Second, how do the different modules within RAG work together to
determine activity? And third, what protects the genome from RAG-mediated transposition and what are
the consequences when those mechanisms fail? These questions are addressed in two interwoven aims:
Aim 1: Determine the underpinnings of DNA recognition and coupled cleavage by RAG and RAG-
family transposases. ProtoRAG transposase binds and cleaves DNA in a manner with striking similarities
to improperly regulated cleavage by RAG. Using novel RAG-ProtoRAG chimeric proteins, biochemistry,
single molecule biophysics, and cryo-EM and x-ray crystallography, we will determine how DNA binding
domains, DNA bending, complex stability, and conformational changes contribute to coordinated vs.
uncoordinated cleavage in synaptic complexes formed by RAG and RAG-like transposases.
Aim 2: Determine the regulation, targeting, and biological consequences of transposition into the
mammalian genome by RAG. Building on our discovery of RAG mutants that uncouple DNA cleavage or
activate transposition in vivo, we will use a suite of in vitro and in vivo transposition, cleavage, and high-
throughput sequencing assays in normal and DNA repair-deficient cells to quantitate and map transposition
mediated by intact and mutant RAG enzymes. In addition, we will generate and analyze RAG-mutant mice
with regulatory defects in DNA cleavage and transposition. Together, our results will reveal how DNA repair
factors and RAG catalytic and regulatory modules have evolved to protect genome stability and shield
developing lymphocytes from malignant transformation during the process of V(D)J recombination.
!
总结
启动V(D)J重组的RAG1/RAG2重组酶是颌型关节炎的一个定义性特征。
脊椎动物的适应性免疫,被认为是从转座因子进化而来的。的关键方面
RAG的生物化学和体内调控尚不清楚,在我们对RAG的理解中留下了很大的空白。
RAG导致基因组不稳定和癌症发展的机制。The Transib
和ProtoRAG转座子,编码RAG样转座酶,提供了一个全新的"工具箱",
来填补这些空白。在未发表的工作中,我们已经:i)确定了ProtoRAG-DNA的结构
复合物通过冷冻电子显微镜(EM); ii)获得晶体的Transib转座酶,
~3 μ m分辨率; iii)确定了指导协调(偶联)DNA的机制的关键组成部分
通过RAG切割;和iv)发现了在体内抑制RAG介导的转座的两种机制。
我们将使用这些新的工具和发现来实现我们的中心目标:
生物化学、结构和调节机制已经进化到协调RAG功能
并确定这些机制失效的生物学后果。我们的建议是
围绕三个核心问题展开。首先,什么机制可以解释RAG的偶联裂解,为什么
这些机制会崩溃吗其次,RAG中的不同模块如何协同工作,
确定活动?第三,是什么保护基因组免受RAG介导的转座,
当这些机制失效时会产生什么后果这些问题在两个相互交织的目标中得到解决:
目的1:确定RAG和RAG-DNA识别和偶联切割的基础。
家族转座酶ProtoRAG转座酶以惊人的相似性结合并切割DNA
RAG的不适当调节切割。使用新的RAG-ProtoRAG嵌合蛋白,生物化学,
单分子生物物理学,冷冻电镜和X射线晶体学,我们将确定如何DNA结合
结构域、DNA弯曲、复合物稳定性和构象变化有助于协调与
在由RAG和RAG样转座酶形成的突触复合物中的不协调切割。
目的2:确定转座到细胞内的调节、靶向和生物学后果。
哺乳动物基因组RAG。基于我们发现的RAG突变体,
激活转座在体内,我们将使用一套在体外和体内转座,切割,和高-
在正常和DNA修复缺陷细胞中进行通量测序测定,以定量和绘制转座图
由完整的和突变的RAG酶介导。此外,我们将产生和分析RAG突变小鼠,
在DNA切割和转座中存在调节缺陷。我们的研究结果将揭示DNA修复
因子和RAG催化和调节模块已经进化到保护基因组稳定性和屏蔽
在V(D)J重组过程中发生恶性转化的淋巴细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David G. Schatz其他文献
Skewing the Playing Field: A Single-Molecule Study on how RSS Sequence Influences Gene Segment Selection
- DOI:
10.1016/j.bpj.2017.11.511 - 发表时间:
2018-02-02 - 期刊:
- 影响因子:
- 作者:
Soichi Hirokawa;Nathan M. Belliveau;Geoffrey A. Lovely;Michael Anaya;David G. Schatz;David Baltimore;Rob Phillips - 通讯作者:
Rob Phillips
Developing B-cell theories
发展 B 细胞理论
- DOI:
10.1038/23134 - 发表时间:
1999-08-12 - 期刊:
- 影响因子:48.500
- 作者:
David G. Schatz - 通讯作者:
David G. Schatz
cDNA representational difference analysis: a sensitive and flexible method for identification of differentially expressed genes.
cDNA代表性差异分析:一种灵敏且灵活的差异表达基因鉴定方法。
- DOI:
- 发表时间:
1999 - 期刊:
- 影响因子:0
- 作者:
Michael Hubank;David G. Schatz - 通讯作者:
David G. Schatz
Transcription elongation factor ELOF1 is required for efficient somatic hypermutation and class switch recombination
转录延伸因子 ELOF1 对于有效的体细胞超突变和类别转换重组是必需的。
- DOI:
10.1016/j.molcel.2025.02.007 - 发表时间:
2025-04-03 - 期刊:
- 影响因子:16.600
- 作者:
Lizhen Wu;Anurupa Devi Yadavalli;Filip Senigl;Gabriel Matos-Rodrigues;Dijin Xu;Andreas P. Pintado-Urbanc;Matthew D. Simon;Wei Wu;André Nussenzweig;David G. Schatz - 通讯作者:
David G. Schatz
Recombination centres and the orchestration of V(D)J recombination
重组中心与 V(D)J 重组的编排
- DOI:
10.1038/nri2941 - 发表时间:
2011-03-11 - 期刊:
- 影响因子:60.900
- 作者:
David G. Schatz;Yanhong Ji - 通讯作者:
Yanhong Ji
David G. Schatz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David G. Schatz', 18)}}的其他基金
FASEB's The Molecular Mechanisms of Immune Cell Development and Function Conference
FASEB 免疫细胞发育和功能的分子机制会议
- 批准号:
10224401 - 财政年份:2021
- 资助金额:
$ 52.53万 - 项目类别:
Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation
人类生发中心 B 细胞发育、恶性肿瘤和体细胞超突变中的基因组结构
- 批准号:
10478178 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation
人类生发中心 B 细胞发育、恶性肿瘤和体细胞超突变中的基因组结构
- 批准号:
10706308 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation
人类生发中心 B 细胞发育、恶性肿瘤和体细胞超突变中的基因组结构
- 批准号:
10117444 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation
人类生发中心 B 细胞发育、恶性肿瘤和体细胞超突变中的基因组结构
- 批准号:
10264152 - 财政年份:2020
- 资助金额:
$ 52.53万 - 项目类别:
Function and Evolutionary Origins of the RAG Endonuclease
RAG 核酸内切酶的功能和进化起源
- 批准号:
10460993 - 财政年份:2018
- 资助金额:
$ 52.53万 - 项目类别:
Function and Evolutionary Origins of the RAG Endonuclease
RAG 核酸内切酶的功能和进化起源
- 批准号:
10801641 - 财政年份:2018
- 资助金额:
$ 52.53万 - 项目类别:
Targeting of somatic hypermutation in the genome
靶向基因组中的体细胞超突变
- 批准号:
10161714 - 财政年份:2017
- 资助金额:
$ 52.53万 - 项目类别:
Targeting of somatic hypermutation in the genome
靶向基因组中的体细胞超突变
- 批准号:
10642885 - 财政年份:2017
- 资助金额:
$ 52.53万 - 项目类别:
The role of AID/APOBEC3 proteins in genome instability in multiple myeloma
AID/APOBEC3 蛋白在多发性骨髓瘤基因组不稳定中的作用
- 批准号:
10165658 - 财政年份:2017
- 资助金额:
$ 52.53万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 52.53万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 52.53万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 52.53万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 52.53万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 52.53万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 52.53万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 52.53万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 52.53万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 52.53万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 52.53万 - 项目类别: